Evidence mapPaperPMID 28060837Full record

Trial reportPloS one2017

Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome.

Catherine Gebhard, Eric Rhéaume, Colin Berry, Geneviève Brand, Anne-Elen Kernaleguen, Gabriel Théberge-Julien, Mohammad Afaque Alam, Candace Y W Lee, Laurianne Boileau, Malorie Chabot-Blanchet and 6 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. HDL and Therapy.Advances in experimental medicine and biology · 2022
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

Catherine GebhardMontreal Heart Institute, Montreal, Quebec, Canada.
Eric RhéaumeMontreal Heart Institute, Montreal, Quebec, Canada.
Colin BerryMontreal Heart Institute, Montreal, Quebec, Canada.
Geneviève BrandMontreal Heart Institute, Montreal, Quebec, Canada.
Anne-Elen KernaleguenMontreal Heart Institute, Montreal, Quebec, Canada.
Gabriel Théberge-JulienMontreal Heart Institute, Montreal, Quebec, Canada.
Mohammad Afaque AlamMontreal Heart Institute, Montreal, Quebec, Canada.
Candace Y W LeeMontreal Heart Institute, Montreal, Quebec, Canada.
Laurianne BoileauMontreal Heart Institute, Montreal, Quebec, Canada.
Malorie Chabot-BlanchetMontreal Heart Institute Coordinating Centre (MHICC), Montreal, Quebec, Canada.
Marie-Claude GuertinMontreal Heart Institute Coordinating Centre (MHICC), Montreal, Quebec, Canada.
Marc-André LavoieMontreal Heart Institute, Montreal, Quebec, Canada.
Jean GrégoireMontreal Heart Institute, Montreal, Quebec, Canada.
Réda IbrahimMontreal Heart Institute, Montreal, Quebec, Canada.
Philippe L'AllierMontreal Heart Institute, Montreal, Quebec, Canada.
Jean-Claude TardifMontreal Heart Institute, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0002-8200-8983
Montreal Heart Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-density lipoproteins (HDL) favorably affect endothelial progenitor cells (EPC). Circulating progenitor cell level and function are impaired in patients with acute coronary syndrome (ACS). This study investigates the short-term effects of reconstituted HDL (rHDL) on circulating progenitor cells in patients with ACS. METHODS AND

findingsThe study population consisted of 33 patients with recent ACS: 20 patients from the ERASE trial (randomized to receive 4 weekly intravenous infusions of CSL-111 40 mg/kg or placebo) and 13 additional patients recruited as controls using the same enrolment criteria. Blood was collected from 16 rHDL (CSL-111)-treated patients and 17 controls at baseline and at 6-7 weeks (i.e. 2-3 weeks after the fourth infusion of CSL-111 in ERASE). CD34+ and CD34+/kinase insert domain receptor (KDR+) progenitor cell counts were analyzed by flow cytometry. We found preserved CD34+ cell counts in CSL-111-treated subjects at follow-up (change of 1.6%), while the number of CD34+ cells was reduced (-32.9%) in controls (p = 0.017 between groups). The level of circulating SDF-1 (stromal cell-derived factor-1), a chemokine involved in progenitor cell recruitment, increased significantly (change of 21.5%) in controls, while it remained unchanged in CSL-111-treated patients (p = 0.031 between groups). In vitro exposure to CSL-111 of early EPC isolated from healthy volunteers significantly increased CD34+ cells, reduced early EPC apoptosis and enhanced their migration capacity towards SDF-1.

conclusionsThe relative increase in circulating CD34+ cells and the low SDF-1 levels observed following rHDL infusions in ACS patients point towards a role of rHDL in cardiovascular repair mechanisms.

Indexed as

Acute Coronary SyndromeAntigens, CD34Cell AdhesionCell MovementCholesterol, HDLEndothelial Progenitor CellsFemaleHumansMaleMiddle AgedPhosphatidylcholinesAntigens, CD34Cholesterol, HDLCSL-111Phosphatidylcholines

Identifiers

PMID28060837
PMCPMC5218493
OpenAlexW2570340122

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.